Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

CCCC holding history

C4 Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CCCC overviewAll 13F holders of CCCCFull Q2 2026 holdings

Shares (Q2 2026)
1,740,989
Value
$8.13M
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of CCCC by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,740,989$8.13M<0.1%+680,658+64.2%AddedHolders
Q1 20261,060,331$2.79M<0.1%+1,007,452+1,905.2%AddedHolders
Q4 202552,879$101.0K<0.1%+41,016+345.7%AddedHolders
Q3 202511,863$26.3K<0.1%−77,612−86.7%ReducedHolders
Q2 202589,475$127.9K<0.1%+10,200+12.9%AddedHolders
Q1 202579,275$126.8K<0.1%+2,796+3.7%AddedHolders
Q4 202476,479$275.3K<0.1%−42,413−35.7%ReducedHolders
Q3 2024118,892$677.7K<0.1%−237,320−66.6%ReducedHolders
Q2 2024356,212$1.65M<0.1%−140,331−28.3%ReducedHolders
Q1 2024496,543$4.06M<0.1%+252,905+103.8%AddedHolders
Q4 2023243,638$1.38M<0.1%−190,472−43.9%ReducedHolders
Q3 2023434,110$807.4K<0.1%−85,069−16.4%ReducedHolders
Q2 2023519,179$1.43M<0.1%+325,018+167.4%AddedHolders
Q1 2023194,161$609.7K<0.1%+108,200+125.9%AddedHolders
Q4 202285,961$507.2K<0.1%−44,121−33.9%ReducedHolders
Q3 2022130,082$1.14M<0.1%+51,294+65.1%AddedHolders
Q2 202278,788$594.0K<0.1%+78,788NewHolders
Q1 20220$00.0%−25,735−100.0%Sold outHolders
Q4 202125,735$829.0K<0.1%+15,852+160.4%AddedHolders
Q3 20219,883$442.0K<0.1%−6,649−40.2%ReducedHolders
Q2 202116,532$626.0K<0.1%+11,102+204.5%AddedHolders
Q1 20215,430$201.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.